99Tcm-tetrofosmin scintigraphy in Hodgkin's disease.
The aim of this study was to assess the suitability of 99Tcm-tetrofosmin (tetrofosmin) scintigraphy as a diagnostic modality in patients with Hodgkin's disease. Fourteen untreated patients with biopsy proven Hodgkin's disease (clinical stage Ia-IVb) were investigated. Post-treatment investigations were also done in 7 of the 14 patients. Focal pathological tetrofosmin uptake was seen in 42 site in the pre-treatment studies. Computed tomography identified 36 pathological regions. The tumour-to-background ratio ranged from 1.44 to 2.17 (mean 1.63). Follow-up studies demonstrated a response to treatment, in that there was a reduction in, or complete disappearance of, localized tetrofosmin uptake in regions previously pathological, and a decrease in tumour-to-background ratios. Tetrofosmin appears suitable for the localization of lymphomatous lesions, especially supradiaphragmatic ones, and for the follow-up of therapeutic response.
Aigner
R M
RM
Department of Radiology, Landeskrankenhaus, Graz, Austria.
Fueger
G F
GF
Zinke
W
W
Sill
H
H
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D015203:Reproducibility of Results; D013997:Time Factors; D014055:Tomography, Emission-Computed
D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; C078700:technetium tc-99m tetrofosmin